Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference [Yahoo! Finance]
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $72.00 price target on the stock.
Avidity Biosciences, Inc. (NASDAQ: RNA) had its price target lowered by analysts at Bank of America Co. from $51.00 to $48.00. They now have a "buy" rating on the stock.
Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $70.00 price target on the stock.